Age Specific Competing Mortality In Breast Cancer Patients - a TEAM Study Analysis

Surgical oncolog

Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis

Development and application of statistical models for medical scientific researc

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)

The aim of this prospective study was to assess the efficacy, clinical benefit and safety of CPT-11 (irinotecan) in patients with stringently- defined 5-fluorouracil-resistant metastatic colorectal cancer (CRC). 107 patients with documented progression of metastatic CRC during 5-FU were treated with CPT-11 350 mg/m2 once every 3 weeks in a multicentre phase II study. Tumor response and toxicity were assessed using WHO criteria. Changes in performance status (PS), weight and pain were also measured. The WHO response rate was 13/95 (13.7%, 95% CI 7.5% to 22.3%) eligible patients with a median duration of response of 8.5 months (37 weeks, range: 18-53 +). There was also a high rate of disease stabilisation (44.2%) with a median duration of 4.8 months. The probability of being free of progression at 4 months was 50%. Median survival from first administration of CPT-11 was 10.4 months or 45 weeks (range: 3-66 + weeks). There was weight stabilisation or gain in 81% (73/90) of patients, a favourable outcome in PS in 91% (82/90) (improvement of WHO PS 2 or stabilisation of PS 0-1), and pain relief in 54% (26/48). There were no toxic deaths. Neutropenia was short-lasting and non-cumulative. Diarrhoea grade ≥ 3 occurred in 7% of cycles and 28/107 (26%) of patients. CPT-11 350 mg/m2 once every 3 weeks has an encouraging degree of activity in progressive metastatic CRC truly resistant to 5-FU with a relatively high rate of tumor growth control translated into clinical benefit. The toxicity profile of CPT-11 is becoming better understood and has been considerably improved.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Qualité de vie de patientes en rémission traitées pour un cancer du sein non métastasé, selon la surveillance médicale classique ou alternée

International audienceObjectif : Évaluer l’impact d’une surveillance alternée du cancer du sein sur la qualité de vie de patientes en rémission et classées selon leur risque histopronostique de récidive (haut-risque [HR] vs bas-risque [BR] de récidive).Méthode : Quinze patientes suivies pour un cancer du sein non métastasé en rémission ont participé à un entretien semidirectif et complété le questionnaire FACT-B évaluant la qualité de vie.Résultats : Le type de surveillance (alternée vs classique) n’affecte pas la qualité de vie des patientes. En revanche, le groupe BR présente une moins bonne qualité de vie que le groupe HR.Conclusion : Les patientes du groupe BR ne semblent pas assez informées sur la surveillance alternée et sur la place que leur médecin généraliste peut et doit prendre durant l’après-traitement. Dans ce contexte, la mise en place d’un suivi psychologique semble pertinente